Key Takeaways
- “Valve disease” is not one diagnosis. The affected valve, stenosis or regurgitation, the underlying mechanism, severity, symptoms, heart response and other cardiac disease determine whether and when to intervene.
- Repair preserves the patient's valve and is often preferred when a durable result is likely, particularly for suitable primary mitral regurgitation. A promised repair rate is not the same as an individual repair plan.
- Mechanical valves are durable but usually require lifelong vitamin K antagonist anticoagulation and reliable INR monitoring. Tissue valves generally avoid lifelong valve-related anticoagulation but can deteriorate and may require another intervention.
- Surgical and transcatheter procedures should be compared by a Heart Team. Age matters, but anatomy, life expectancy, pregnancy plans, bleeding risk, kidney disease, vascular access, future valve-in-valve options and patient preference also matter.
- Before cross-border treatment, confirm the exact device or repair, postoperative antithrombotic plan, baseline echocardiogram, endocarditis advice, follow-up schedule and who will manage anticoagulation at home.
Content
A heart valve decision begins long before choosing an implant. The aortic, mitral, tricuspid and pulmonary valves fail for different reasons; a valve can become narrowed, leak, or do both. Degenerative disease, rheumatic damage, infection, congenital anatomy, ventricular enlargement and a failing prior prosthesis can produce similar symptoms but require different treatment.
The 2025 ESC/EACTS guideline places the Heart Team, specialist valve centres, advanced imaging and patient-centred decision-making at the centre of complex valve care.[1] For an international patient, that means the useful comparison is not “repair versus replacement” in the abstract. It is a documented comparison of feasible options for this valve, at this stage, in this patient.
Confirm the lesion before discussing the operation
Ask the cardiologist to state the diagnosis in one line:
Valve + lesion + mechanism + severity + ventricular response + symptoms.
For example, “severe primary degenerative mitral regurgitation from posterior-leaflet prolapse, with preserved left-ventricular function and exertional breathlessness” is actionable. “Bad mitral valve” is not.
The assessment may require transthoracic echocardiography, transoesophageal echocardiography, CT, cardiac MRI, exercise testing, catheterisation or coronary angiography, depending on the lesion and proposed treatment. Measurements should be interpreted together: valve area or regurgitation grade, gradients and flow, chamber size, pumping function, pulmonary pressure and symptom burden.
Discordant results deserve review. A severe-looking valve with few symptoms may need exercise assessment; low-flow aortic stenosis can require additional testing; secondary mitral regurgitation must be assessed alongside ventricular disease and guideline-directed heart-failure treatment. Repeating one familiar test is not always the answer.
Timing is part of treatment quality
Waiting until a patient is visibly unwell can allow irreversible ventricular or pulmonary damage. Operating too early can expose a person to prosthesis-related risks before benefit is clear. Ask what threshold has been reached, which measurement is being trended and what would trigger intervention if the patient waits.
The written recommendation should classify the situation as:
- urgent because of acute severe regurgitation, infection, instability or another high-risk feature;
- time-sensitive because symptoms, ventricular changes or pulmonary pressure meet an intervention threshold; or
- surveillance, with a specific echocardiography and symptom-review interval.
New breathlessness at rest, fainting, chest pressure, rapidly increasing swelling, fever with possible valve infection or sudden neurological symptoms require local assessment rather than an elective international appointment.
When can a valve be repaired?
Repair reshapes or supports the patient's own valve. Techniques can include removal or reconstruction of abnormal leaflet tissue, artificial chordae, commissurotomy, patching or an annuloplasty ring. Catheter-based repair is possible for selected lesions. The American Heart Association notes that retaining native tissue is generally preferable when a dependable repair is possible, but damaged tissue may require replacement.[2]
Repair suitability is valve- and mechanism-specific. A focal degenerative mitral prolapse can be very different from rheumatic restriction, extensive calcification, active infection or regurgitation caused mainly by a dilated ventricle. Aortic and tricuspid repair are also possible in selected anatomy but require particular expertise.
Ask the surgeon:
- Which component is abnormal, and what repair manoeuvres are planned?
- What is the expected likelihood of a durable repair for this anatomy—not the programme average?
- How will the result be tested in theatre?
- What residual leak or gradient would be accepted?
- What finding would trigger replacement, and which prosthesis would then be used?
- How many comparable repairs does the surgeon and centre perform?
The consent should include the fallback. “Repair intended” does not guarantee that replacement will never be necessary once the valve is inspected.
Mechanical and tissue valves solve different lifetime problems
When replacement is required, the central comparison is usually between a mechanical prosthesis and a biological or tissue valve. Mechanical valves use durable manufactured materials. Tissue valves are made from treated animal or human tissue and can be implanted surgically; transcatheter valves are also biological prostheses.[3]
Consideration · Mechanical valve · Tissue valve
Durability · Generally greatest · Structural deterioration can occur over time
Anticoagulation · Usually lifelong vitamin K antagonist with INR monitoring · Long-term valve-related anticoagulation is often avoidable, but early therapy and other indications vary
Bleeding and clot risk · Closely tied to anticoagulation quality and valve factors · Lower lifelong anticoagulation burden, but thrombosis is still possible
Reintervention · Less likely for structural wear · Future redo surgery or valve-in-valve treatment may be needed
Pregnancy · Anticoagulation creates major maternal and fetal complexity · Durability and future reintervention must be weighed against anticoagulation
Daily life · Regular INR access, interactions and procedure planning matter · Ongoing valve surveillance still required
No fixed age cut-off answers the question. The AHA advises considering age together with disease extent, valve size, willingness to take medication and individual preferences.[3] A younger patient may reasonably prioritise avoiding reoperation or avoiding lifelong anticoagulation; either choice carries consequences. A small surgical tissue valve can also limit a future valve-in-valve procedure, so future options should be modelled before the first operation.
Anticoagulation feasibility must be tested before choosing a mechanical valve
Mechanical valves require vitamin K antagonist therapy, most commonly warfarin, at an INR target determined by valve position, type and thromboembolic risk. Direct oral anticoagulants are not substitutes for mechanical-valve anticoagulation. The 2020 ACC/AHA guidance lists different INR targets and explicitly contraindicates direct thrombin and anti-Xa oral anticoagulants for mechanical prostheses.[4]
Before treatment abroad, answer practical questions:
- Where can INR be checked at home, and how quickly are results returned?
- Who changes the dose and covers weekends or travel?
- Is the same warfarin formulation consistently available?
- What happens if antibiotics, diet, vomiting or another medicine changes the INR?
- Who plans interruption or bridging for surgery, endoscopy or dental procedures?
- Is pregnancy possible or planned?
Do not choose a valve on the assumption that anticoagulation can be “worked out later.” Conversely, do not assume a tissue valve means no antithrombotic treatment: the early postoperative regimen and coexisting atrial fibrillation, venous thrombosis or coronary disease can still require it.
Compare open, minimally invasive and transcatheter routes honestly
Open surgery can repair or replace valves and address coronary disease, the aorta, additional valves or atrial fibrillation in the same operation. Minimally invasive or robot-assisted surgery uses smaller access but remains heart surgery and depends on anatomy and centre experience. Transcatheter options include TAVI/TAVR for aortic stenosis and selected repair or replacement technologies for mitral and tricuspid disease.
The correct route depends on surgical risk, anatomy, age and life expectancy, vascular access, coronary height, annulus size, calcification, need for other cardiac procedures, prior surgery, pacemaker risk and expected durability. The 2025 European guideline specifically updates indications and timing for surgical and transcatheter options and stresses complex-patient management in Heart Valve Centres.[1]
Ask each team to state what its option cannot accomplish. A catheter procedure may avoid sternotomy but may leave another valve, coronary lesion or aorta untreated. Surgery may provide a more comprehensive repair but with a different recovery and perioperative risk. A small incision is not a clinical outcome.
Plan the operation and its fallback in writing
For surgical treatment, obtain a preliminary plan covering:
- repair versus replacement and the intraoperative decision rule;
- prosthesis manufacturer, model and size range under consideration;
- sternotomy or minimally invasive access, and conversion plan;
- heart-lung bypass and expected concomitant procedures;
- coronary bypass, aortic work, additional valve surgery or surgical ablation if relevant;
- blood-management and transfusion strategy;
- neurological, kidney, rhythm, bleeding and infection risks; and
- intensive-care and ward expectations.
Individual risk should be quantified where possible. The STS adult cardiac risk calculator supports procedure-specific estimates of mortality, major morbidity and short-term outcomes for many valve operations, including combined procedures.[5] A model informs shared decision-making; it does not replace surgical judgement or local outcome data.
Recovery depends on the route and the whole operation
After open valve surgery, patients usually begin in intensive care with a breathing tube, drains, monitoring lines and sometimes temporary pacing wires. Priorities include haemodynamic stability, bleeding, rhythm, neurological status, kidney function, pain, breathing exercises and mobilisation. Atrial fibrillation, conduction problems, fluid retention, anaemia, delirium and wound complications can change the timeline.
Transcatheter treatment often has a shorter initial recovery, but vascular injury, bleeding, stroke, valve leak, kidney injury or a new pacemaker requirement can still occur. “Discharge in two days” is a possibility for selected uncomplicated patients, not a contractual outcome.
For sternotomy, follow the surgeon's instructions on lifting, pushing, driving and wound care. AHA recovery material advises monitoring temperature, weight, swelling, wound changes, sleep, appetite and mood after heart surgery.[6] The plan should translate those observations into thresholds and local contacts.
A prosthetic-valve passport is essential for cross-border care
Before leaving China, obtain:
- final diagnosis and preoperative echocardiography images and report;
- operative or catheter procedure note;
- repair details, ring or device identifiers, or prosthesis manufacturer, model, size and serial/lot data where available;
- implant card;
- postoperative baseline echocardiogram;
- complications, transfusions, rhythm and pacemaker information;
- anticoagulant or antiplatelet names, targets and durations;
- wound, activity, travel and rehabilitation instructions;
- endocarditis-prevention and dental-care advice specific to the repair or prosthesis; and
- timing and owner of the next clinical review and echocardiogram.
ACC/AHA guidance recommends baseline imaging after the procedure and later surveillance, with earlier additional imaging when symptoms or signs suggest valve dysfunction.[4] Keep the baseline study itself, not only a translated summary, because future teams need to compare gradients, regurgitation and ventricular function.
Medical disclaimer: This guide provides general education, not an individual recommendation on timing, repair, prosthesis or anticoagulation. Acute breathlessness, fainting, chest symptoms, neurological change or possible valve infection requires immediate local assessment.
FAQ
Is valve repair always better than replacement?
Repair is often attractive because it preserves native tissue, but it is better only when a durable, competent valve is likely. Mechanism, calcification, infection, ventricular disease and centre expertise matter.[2] The consent should include a replacement fallback.
How long does a tissue valve last?
There is no guaranteed lifespan. Durability varies with valve type and position, age, calcium metabolism, kidney disease and other factors. AHA patient material describes tissue valves as potentially lasting around 10–20 years, but individual performance can be shorter or longer.[3]
Can a mechanical-valve patient take a direct oral anticoagulant instead of warfarin?
No. Current ACC/AHA guidance contraindicates direct thrombin and anti-Xa oral anticoagulants for mechanical prosthetic valves.[4] A vitamin K antagonist with the correct valve-specific INR target is required unless a specialist changes the plan based on future evidence.
Is a transcatheter valve always safer than open surgery?
No. It avoids an open operation for suitable patients, but has its own anatomical limits and risks and may not address other cardiac disease. A Heart Team should compare early risk, durability, pacemaker and leak risk, future coronary access and later reintervention.[1]
What record matters most after valve treatment abroad?
Carry the procedure report and implant or repair details together with the baseline postoperative echocardiogram and antithrombotic plan. An implant card alone does not show gradients, residual regurgitation, complications or the next surveillance date.
Sources
- European Society of Cardiology — 2025 ESC/EACTS Guidelines for Valvular Heart Disease
- American Heart Association — Options for Heart Valve Repair
- American Heart Association — Options for Heart Valve Replacement
- American College of Cardiology — 2020 ACC/AHA Heart Valve Disease Guideline, Part 3
- Society of Thoracic Surgeons — ACSD Operative Risk Calculator
- American Heart Association — What Can I Expect When I Go Home After Heart Surgery?
Image Review
- Decision: Replaced with a topic-specific ImageGen hero and visually reviewed for medical relevance, obvious generation artifacts and bilingual reuse.
- Editorial note: The original image is a generic consultation with a decorative valve-like heart symbol. It does not compare repair with mechanical or tissue replacement and could be mistaken for branding rather than anatomy.